MITOTECH

New possibilities opened up only in the beginning of this century. In 2004, a new substance was synthesized by the group of professor Vladimir P. Skulachev in the Moscow State University. Our project team later gave the substance its “production” name “SkQ1".

Two commercial entities Mitotech Russia and Mitotech EU were established around 2010 with an aim to develop SkQ1 into a drug targeting several age-related indications. Targeted therapeutic areas include ophthalmic and neurodegenerative disorders. The companies are running their clinical programs in different geographical markets with a common goal of making SkQ1-based drugs available to patients world-wide.

Research is Vladimir Petrovich Skulachev, biochemist, Academician of the Russian Academy of Sciences, Dean of the founding of the Faculty of Bioengineering and Bioinformatics, Moscow State University, and a team of about 100 professionals.

THEORY: reactive oxygen species are known to present serious danger for living cells and whole organisms, especially with age.

TECHNOLOGY: SkQ1 reduces reactive oxygen species production inside mitochondria in a controlled and sustainable manner.

RESULTS: Several SkQ1-based drugs targeting various age-related disorders are being developed in our labs.